Globe Small Cap Research Report: OncBioMune Pharmaceuticals

Globe Small Cap Research announced a report on OncBioMune Pharmaceuticals (OTCMKTS:OBMP) highlighting a positive risk/reward ratio to these shares at the current price.
As quoted in the report:

Summary of Our Research Findings

• This report offers an analysis of OncBioMune Pharmaceuticals, Inc. We believe there is a positive risk/reward ratio to these shares at the current price.
• OncBioMune is a fully reporting early clinical stage pharmaceutical company developing a new type of cancer treatment based on a proprietary vaccine technology. The initial target market is prostate cancer.
• With very encouraging Phase 1 results, the Company is expected to soon announce details of its Phase 2 study.
• Approximately 230,000 new cases of prostate cancer will be diagnosed this year and there will be more than 28,000 deaths. Current treatments are lacking, especially for early stages cases. OBMP’s prostate cancer vaccine can treat patients at any stage of the disease and, importantly, is specifically targeting the unaddressed early stage treatment market.
• Financing has recently been put into place, which should allow the Company to fully finance the Phase 2 clinical study.
• OncBioMune in March signed an agreement with Vitel Laboratorios S.A. de C.V. to establish a Joint Venture for the purpose of development and commercialization of ProscaVax for the Mexican and Latin American markets.
• With a total market capitalization of only about $25 million, the price of shares is very reasonable considering the potential size of the market opportunity and the likely positive news flow.
• In addition to its therapy for prostate cancer, the Company has an attractive pipeline, with its ovarian cancer therapy called OvcaVax, targeted transferrin transport technologies and biosimilars to approved drugs, including the blockbuster Abraxane.
• Over the coming weeks, we will be watching closely for news relative details of the pending Phase 2 trial.

Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.